Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression

Eitemau Tebyg

• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2013)
• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2012)
• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2013)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2016)
• Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2012)